欢迎来到天天文库
浏览记录
ID:55682500
大小:162.43 KB
页数:2页
时间:2020-05-24
《阿德福韦酯治疗慢性乙型肝炎原发性无应答患者基因型耐药分析.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、182JBengbuMedColl,February2014,Vo1.398,No.2[文章编号]1000—2200(2014)02-0182-02·临床医学·阿德福韦酯治疗慢性乙型肝炎原发性无应答患者基因型耐药分析张礼周,张振华,梁佳佳,方立庆,李旭[摘要]目的:观察阿德福韦酯治疗慢性乙型肝炎原发性无应答患者基因型耐药的发生情况。方法:阿德福韦酯治疗慢性乙型肝炎原发性无应答患者155例,应用荧光定量PCR法检测其aN236T、rtA181V、rtA181T耐药位点。结果:155例患者共检出基因型耐药16
2、例,发生率为10.3%,其中rtN236T位点3例、rtA181V位点7例、rtA181T位点2例、rtA181V+rtA181T位点2例、rtA181T+rtN236T位点1例、rtN236T+~A181V+rtA181T位点1例。结论:阿德福韦酯治疗慢性乙型肝炎原发性无应答患者基因型耐药发生率并不高,疗效不佳可能与阿德福韦酯抑制乙型肝炎病毒DNA能力较弱,病毒水平下降速度较慢有关。[关键词]乙型肝炎;阿德福韦酯;基因型耐药;原发性无应答[中国图书资料分类法分类号]R512.62[文献标志码]AAnal
3、ysisofgenotypieresistanceofprimarynon-responsepatientsfollowingchronichepatitiaBvirusinfectiontreatedwithadefovirdipivoxilZHANGLi.zhou,ZHANGZhen—hua,LIANGJia-jia,FANGLi—qing,LIXu(J.DepartmentofInfectiousDiseases,TaihePeopleSHospital,TaiheAnhui236604;2.Dep
4、artmentofInfectiousDisease,TheFirstAffiliatedHospitalofAnhuiMedicalUniversity,HefeiAnhui230022,China)[Abstract]objective:Todeterminethegenotypicresistanceofprimarynon—responsepatientsfollowingchronichepatitiaBvirusinfectiontreatedsinglywithadefovirdipivox
5、il.Methods:Onehundredfifty—fivecasesofprimarynon—responsepatientsfollowingchronichepatitiaBvirusinfectiontreatedwithadefovirdipivoxil,rtN236T,rtA181V,rtA181TofthemweredeterminedbyfluorescencequantitativePCRmethod.Results:Sixteencasesofthegenotypicresistan
6、ceweredetermined,theratioofincidencewas10.3%,includingthreecasesofrtN236T,sevencasesofrtA181V,twocasesofrtA181T,twocasesofrtA181V+rtA181T,onecaseofrtA181T+rtN236TandonecaseofrtN236T+rtA181V+rtA181T.Conclusions:Thepresentstudyconfirmedtheratioofincidenceof
7、thegenotypicresistanceofprimarynon—responsepatientsfollowingchronichepatitiaBvirusinfectiontreatedsinglywithadefovirdipivoxilwaslow.ThepooreficacymaybethattheinhibitioneffectontheabilityofHBVDNAisweak,droppedspeedoftheviruslevelsisslow.[Keywords]hepatitis
8、B;adefovirdipivoxil;genotypicresistance;primarynon-response阿德福韦酯(adefovirdipivoxil,ADV)是继拉米患者中基因型耐药的发生率及耐药位点的情况。夫定(LAM)之后于2002年上市的治疗慢性乙型肝1资料与方法炎(CHB)的核苷类似物,2005年被中国《慢性乙型肝炎防治指南》推荐为一线抗病毒药物而广泛应用1.1一般资料155例为2009年9月至2011
此文档下载收益归作者所有